New Study Offers Hope for GLP-1 Medication Users After Stopping Treatment
With the rising popularity of injectable medications like Ozempic, Wegovy, and Zepbound, many users are curious about what happens when they stop these treatments. Previous studies raised concerns about a “rebound” effect, where individuals would quickly regain lost weight after ending their medication. However, a new study from the Cleveland Clinic, featured in the journal Diabetes, Obesity and Metabolism, presents a more optimistic outlook.
The study analyzed nearly 8,000 adults from Ohio and Florida who used semaglutide or tirzepatide for a period ranging from three to twelve months before discontinuing. Unlike controlled clinical trials, this research focused on real-world scenarios, where patients frequently switch medications.
The findings reveal that most patients did not regain a lot of weight after stopping GLP-1 treatments. For those who used the medication primarily for obesity, the average weight loss before stopping was 8.4%. A year later, they had regained only about 0.5% of that weight.
Lead author Dr. Hamlet Gasoyan shared insights, stating, “Our data show that many patients who stop semaglutide or tirzepatide often restart the medication or switch to another treatment, which may explain the lesser weight regain compared to those in randomized trials.”
This suggests that the rebound effect seen in clinical settings might be due to patients not receiving ongoing support, which is less common in everyday medical practice. Around 27% of patients shifted to different medications, possibly older obesity drugs, while another 20% resumed their original treatment once any issues were resolved.
Additionally, about 14% of participants moved to intensive lifestyle change programs, collaborating with dietitians and exercise professionals. Researchers noted that patients who managed to maintain their weight often stayed connected with healthcare services through alternative prescriptions or structured support.
It’s essential to highlight that the study has its limitations. It focused on adult patients from a particular health system in Ohio and Florida, which might not represent healthcare practices across the U.S.
In future work, the researchers aim to explore the effectiveness of various obesity treatment options for patients who stop using semaglutide or tirzepatide, helping both patients and their doctors make informed choices.
